What is the 13F Pro Quality Score for MED?

13F Pro ranks MEDIFAST INC (MED) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MED's current score at https://13fpro.ai/research/MED (free sign-up required for the full ranking).

Which hedge funds own the most MED stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MED include BlackRock,, RENAISSANCE TECHNOLOGIES, CITADEL ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/MED as soon as new 13F filings post.

Where does 13F Pro source MED data?

All MEDIFAST INC fundamentals and ownership data come directly from SEC EDGAR. MEDIFAST INC files with the SEC under CIK 910329. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MED in?

MEDIFAST INC (MED) is classified in the Consumer Staples sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/consumer-staples.

How often is MED research updated on 13F Pro?

MED's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MEDIFAST INC(MED)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Consumer Staples →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 910329 MED stock profile & AI dashboard →

13F Pro Quality Score

30.1/100

Rank #2,371 of 2,879 stocks

View Consumer Staples peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

2.3/100

Profitability

28.3/100

Balance Sheet

31.8/100

Earnings Quality

30.0/100

Free Cash Flow

39.9/100

Institutional Flow

94.6/100

Revenue Scale

33.0/100

Dilution Risk

41.6/100

MED Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MEDIFAST INC (MED), a Consumer Staples sector company. 13F Pro's AI-powered ranking engine scores MED at 30.1/100 on a 32-signal composite quality model, placing it at rank #2,371 of 2,879 stocks — the bottom half of the AI-ranked universe. MED scores in the top quartile across institutional flow (94.6). Areas of concern include revenue growth (2.3) and profitability (28.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 41.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), MEDIFAST INC reports quarterly revenue of $76.0M, net income of $-2.1M, an operating margin of -4.3%. Top institutional holders of MED by reported 13-F value include BlackRock,, RENAISSANCE TECHNOLOGIES, CITADEL ADVISORS, based on the most recent SEC filings. MED trades on the NYSE exchange and files with the SEC under CIK 910329. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MED daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MEDIFAST INC directly from SEC EDGAR. MEDIFAST INC's 13F Pro composite quality score has ranged between 8 and 74 since 2021, currently 30.1 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about MEDIFAST INC

Quirks, history, and lore behind MED — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. consumer staples company · small-cap · listed on the NYSE · headquartered in Maryland.
2
The Numbers
Annual revenue in the range of $700 million to $1 billion, with a business model built almost entirely on recurring customer purchases rather than one-time sales.
3
The History
Founded in the early 2000s, it grew rapidly by combining meal-replacement products with a coach-based sales network — no brick-and-mortar stores required.
4
The Secret
Its real product isn't food — it's a behavior-change program where certified health coaches (many of them former customers) guide clients through a structured weight-loss plan.
5
The Lore
At its peak it had over 50,000 active coaches selling its program, making it one of the largest direct-sales wellness businesses in America — without most people ever having heard of it.
6
The Giveaway
Its flagship program is called OPTAVIA — lean-and-green meals, portion-controlled "fuelings," and a coach in your corner. The ticker is practically a medical abbreviation.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$76.0M

Net Income

Q1 2026

$-2.1M

Free Cash Flow

Q1 2026

$-836.0K

Operating Margin

Q1 2026

-4.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-32.9% YoY

$1.07BFY 2023

FY20 $934.8MFY21 $1.53BFY22 $1.60BFY23 $1.07B

Net Income

-31.0% YoY

$99.4MFY 2023

FY20 $102.9MFY21 $164.0MFY22 $144.0MFY23 $99.4M

Operating Income

-31.6% YoY

$126.4MFY 2023

FY20 $134.2MFY21 $216.2MFY22 $184.8MFY23 $126.4M

EPS (Diluted)

-28.5% YoY

$9.10FY 2023

FY20 $8.68FY21 $13.89FY22 $12.73FY23 $9.10

Total Assets

-2.0% YoY

$309.9MFY 2023

FY20 $276.1MFY21 $398.3MFY22 $316.2MFY23 $309.9M

Total Debt

—FY 2023

FY20 —FY21 —FY22 —FY23 —

Op. Cash Flow

-24.1% YoY

$147.7MFY 2023

FY20 $145.2MFY21 $94.5MFY22 $194.6MFY23 $147.7M

Metric	FY 2023	FY 2022	FY 2021	FY 2020	FY 2016	FY 2013
Revenue	$1.07B -32.9%	$1.60B +4.8%	$1.53B +63.2%	$934.8M +240.5%	$274.5M -15.3%	$324.1M
Net Income	$99.4M -31.0%	$144.0M -12.2%	$164.0M +59.4%	$102.9M +476.7%	$17.8M -25.6%	$24.0M
Operating Income	$126.4M -31.6%	$184.8M -14.5%	$216.2M +61.2%	$134.2M +399.5%	$26.9M -30.1%	$38.4M
EPS (Diluted)	$9.10 -28.5%	$12.73 -8.4%	$13.89 +60.0%	$8.68 +482.6%	$1.49 -13.9%	$1.73
Total Assets	$309.9M -2.0%	$316.2M -20.6%	$398.3M +44.3%	$276.1M +127.8%	$121.2M -8.6%	$132.7M
Total Debt	—	—	—	—	—	$222.0K
Operating Cash Flow	$147.7M -24.1%	$194.6M +105.8%	$94.5M -34.9%	$145.2M +472.8%	$25.4M -40.2%	$42.4M

AI Insight: MED Financial Trends

Revenue collapsed 55% from $169M in Q2 2024 to $76M in Q1 2026 with persistent losses and deteriorating cash generation.

• Revenue declined from $169M in Q2 2024 to $76M in Q1 2026, a 55% drop over seven quarters.

• Operating income turned negative in Q2 2024 and remained unprofitable, falling to -$3M in Q1 2026.

• Equity declined from $211M in Q1 2025 to $198M in Q1 2026 amid accumulated losses.

⚠ Operating cash flow volatile, swinging from $12M in Q3 2025 to -$5M in Q4 2025 to $0M in Q1 2026.

⚠ Sequential revenue stabilized at $75M-$76M in latest two quarters after steep prior declines.

AI Insight: MED Ratio Trends

Medifast shows severe profitability deterioration with operating margin plunging to -10.4% in Q4 2025, the worst quarterly performance in the dataset.

• Operating margin collapsed from 1.5% in Q3 2024 to -10.4% in Q4 2025, marking sustained negative territory.

• ROE turned deeply negative, falling from 2.2% in Q3 2024 to -36.4% in Q4 2025.

• ROIC deteriorated from 4.1% in Q3 2024 to -15.7% in Q4 2025, indicating value destruction.

⚠ Q1 2026 shows partial recovery with operating margin improving to -4.3% from Q4 2025's -10.4%.

⚠ Net profit margin remains volatile, swinging from 2.4% in Q2 2025 to -24.1% in Q4 2025.

Get alerted when MED's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MEDIFAST INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MED

BlackRock, Inc.
$9.6M944,453 sh
RENAISSANCE TECHNOLOGIES LLC
$7.9M773,710 sh
CITADEL ADVISORS LLC
$7.3M712,800 sh
Steamboat Capital Partners, LLC
$7.2M707,590 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$6.4M631,539 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.5M444,467 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$4.4M435,400 sh
GROUP ONE TRADING, L.P.
$3.9M378,700 sh
DIMENSIONAL FUND ADVISORS LP
$3.7M361,762 sh
TWO SIGMA INVESTMENTS, LP
$3.4M338,158 sh

Fund	Value	Shares
BlackRock, Inc.	$9.6M	944,453
RENAISSANCE TECHNOLOGIES LLC	$7.9M	773,710
CITADEL ADVISORS LLC	$7.3M	712,800
Steamboat Capital Partners, LLC	$7.2M	707,590
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$6.4M	631,539
VANGUARD CAPITAL MANAGEMENT LLC	$4.5M	444,467
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$4.4M	435,400
GROUP ONE TRADING, L.P.	$3.9M	378,700
DIMENSIONAL FUND ADVISORS LP	$3.7M	361,762
TWO SIGMA INVESTMENTS, LP	$3.4M	338,158

More Consumer Staples Companies

View all Consumer Staples →

ABEV

AMBEV S.A.

ABVE

Above Food Ingredients Inc.

ACI

Albertsons Companies, Inc.

ADM

Archer-Daniels-Midland Co

AFRI

Forafric Global PLC

AGCC

Agencia Comercial Spirits Ltd.

AGRO

Adecoagro S.A.

AGRZ

Agroz Inc.

Put MED on your watchlist

Track score changes the day MEDIFAST INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MED a good stock to buy?

13F Pro's AI-powered analysis of MEDIFAST INC (MED) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Consumer Staples sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MED are available on the MED stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MED?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MED. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MEDIFAST INC's investment landscape.